



April 9, 2012

3-D Matrix, Ltd.

**Memorandum of Understanding concluded**  
**with Fuso Pharmaceutical Industries, Ltd. and Kaken Pharmaceutical Co., Ltd.**  
**regarding sales of absorbable local hemostat (TDM-621)**

3-D Matrix, Ltd. ("3DM"), Fuso Pharmaceutical Industries, Ltd. ("Fuso", head office located in Osaka, President Mikio Toda), and Kaken Pharmaceutical Co., Ltd. ("Kaken", head office located in Tokyo, President Tetsuo Onuma) reached and entered into a memorandum of understanding for sales collaboration in Japan about the absorbable local hemostat (develop code: TDM-621) which is developed by 3DM and under application of manufacturing and marketing approval as medical device.

Fuso and Kaken will distribute TDM-621 according to this memorandum. Both companies will promote to market TDM-621 rapidly and provide medical professions with information on proper use, by marketing ability and know-how in surgery field which are developed in sales of adhesion prevention device.

3DM thinks that this memorandum of agreement leads to our corporate structure where we can promote to maximize product sales with strengthened sales system and expanded sales channel.

**<About absorbable local hemostat (TDM-621) developed by 3DM>**

Regarding TDM-621, 3DM and Fuso entered into an exclusive distribution license agreement on July 21, 2009 and 3DM grants Fuso an exclusive distribution right in Japan. 3DM has applied manufacturing and marketing approval of TDM-621 in Japan as medical device in May, 2011.

TDM-621 is clear liquid made with peptide consisting of three kinds of amino acid which are constituents of human body. TDM-621 is used in general surgery operations and stops bleeding by blocking up blood vessel physically using its feature to foam hydro gel instantly upon touching blood (self-assembling). This peptide has no risk of infection with hepatitis C virus as it is made by chemical synthesis and has an advantage to keep out animal derived materials.

The effect on the earning forecast of this fiscal year of 3DM and "Mid-term business plan" on October 24, 2011 is now under review and going to be disclosed immediately.